← Research library

Treatment of asthenic syndrome in chronic brain ischemia: TRIUMPH observational program

Observational study · 2014

What was studied
2,029 participants; 1,170 analyzed; 859 excluded for protocol completion/documentation problems
Main finding
Fatigue scores declined in an observational program, with large exclusions from analysis and no untreated group.

General-fatigue reduction at three months · 59.1%, 55.9%, 60.5% and 55.7% · Four age-by-duration subgroups; within-person reductions, not a placebo-adjusted effect · Three months after treatment started

Reported findings and study design

Fatigue scores declined in an observational program, with large exclusions from analysis and no untreated group.

2,029 enrolled; 1,170 analyzed; 859 excluded for protocol/documentation problems. Physicians chose two or three months of 100 mg/day treatment.

Results · Publisher full-text results narrative and available tables checked on 1 November 2026
MeasureResultComparison, timing and statistics
General-fatigue reduction at three months59.1%, 55.9%, 60.5% and 55.7%Four age-by-duration subgroups; within-person reductions, not a placebo-adjusted effect · Three months after treatment started
Post-treatment MFI-20 score33.3 points in younger patients; 37.0 in older patientsAges 45–54 and 55–65; reported overall baseline score 77 · Final follow-up
Baseline severity versus subsequent reductionr=0.789Correlational association · p=0.001
Analysis population1,170 of 2,029 participants859 records excluded; not all enrollment contributed to results
Reported fatigue reductions by age and treatment duration
Reported fatigue reductions by age and treatment duration
Age / courseGeneral fatiguePhysical fatigueReduced activityReduced motivationMental fatigue
45–54 / 2 months59.1%53.9%57.0%49.8%58.6%
55–65 / 2 months55.9%48.6%53.4%47.6%55.6%
45–54 / 3 months60.5%50.7%58.9%52.2%58.6%
55–65 / 3 months55.7%46.9%54.0%50.0%55.4%

Reductions from each subgroup baseline at three months after initiation; the two-month groups were assessed one month after stopping. The narrative does not provide subgroup denominators here.

Treatment duration was not randomized and there was no placebo or untreated comparator. The table preserves each subgroup rather than assigning the largest percentage to the whole cohort.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Large exclusion from analysis creates potential selection bias.
  • No untreated control; within-person improvement cannot establish causation.
  • This program is not a randomized trial and cannot establish long-term safety.

Source details

Publisher HTML article

Publisher full-text results narrative and available tables checked on 1 November 2026

Sources checked

Citation

Uncontrolled human reportFull text available

A. I. Fedin, E. Yu. Solovyeva, O. P. Mironova, A. V. Fedotova. Treatment of asthenic syndrome in chronic brain ischemia: TRIUMPH observational program Zh Nevrol Psikhiatr Im S S Korsakova. 114(12):104–111

Study source ↗ · DOI 10.17116/jnevro2014114121104-111 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards